Lilly Pumps $3B Into China to Boost Supply of Weight-Loss Pill
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
Lilly Pumps $3B Into China to Boost Supply of Weight-Loss Pill Read More »
